PER Committee Admits Czech Republic To Scheme

17 November 1997

Having considered and examined the application of the Czech registrationauthority concerning its pharmaceutical registration system, the permanent committee of the Scheme for the Mutual Recognition of Evaluation Reports on Pharmaceutical Products (PER Scheme) has agreed to the participation of the Czech authority into the Scheme, effective January 1, 1998.

At a meeting of the PER committee earlier this month, held at the offices of the South African Department of Health and chaired by SA's Professor Antoine van Gelder, the operation of the Scheme overall was reviewed, and it was considered to be still extremely valuable by the participating authorities of the non-European Union countries.

More than 100 requests for evaluation reports were made in 1996, and over 600 in the first nine months of 1997. According to a PER statement, the figure for this year is particularly impressive, given that the introduction of the entralized and mutual recognition procedures between EU member states and the European Economic Area has inevitably reduced the numbers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight